{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T10:37:18Z","timestamp":1783161438255,"version":"3.54.6"},"reference-count":42,"publisher":"Informa UK Limited","issue":"11","license":[{"start":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1080\/03007995.2024.2416979","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T15:16:18Z","timestamp":1729610178000},"page":"1993-2002","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Baricitinib as monotherapy for treatment of rheumatoid arthritis: analysis of real-world data"],"prefix":"10.1080","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8233-6602","authenticated-orcid":false,"given":"Christoper J.","family":"Edwards","sequence":"first","affiliation":[{"name":"MSK Research Unit, NIHR Southampton Clinical Research Facility","place":["Southampton, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1111-8218","authenticated-orcid":false,"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Saitama Medical University","place":["Saitama, Japan"]},{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1210-4347","authenticated-orcid":false,"given":"Axel","family":"Finckh","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Geneva University Hospital (HUG)","place":["Geneva, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2026-7728","authenticated-orcid":false,"given":"Arnd","family":"Kleyer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 3, Rheumatology and Immunology, University Hospital Erlangen and Friedrich-Alexander University (FAU) Erlangen-N\u00fcrnberg","place":["Erlangen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Haladyj","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company","place":["Indianapolis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens Gammeltoft","family":"Gerwien","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company","place":["Indianapolis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Treuer","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company","place":["Indianapolis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Zaremba-Pechmann","sequence":"additional","affiliation":[{"name":"HaaPACS GmbH","place":["Schriesheim, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4302-8877","authenticated-orcid":false,"given":"Josef S.","family":"Smolen","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine 3, Medical University of Vienna","place":["Vienna, Austria"]},{"name":"2nd Department of Medicine, Hietzing Hospital Vienna","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,10,22]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24596"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000284"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/39.9.975"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.023408"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21519"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39953"},{"issue":"5","key":"e_1_3_5_9_1","first-page":"862","article-title":"Monotherapy is a relevant option in rheumatoid arthritis treatment: a literature review","volume":"37","author":"Doria A","year":"2019","unstructured":"Doria A, Zavaglia D. Monotherapy is a relevant option in rheumatoid arthritis treatment: a literature review. Clin Exp Rheumatol. 2019;37(5):862\u2013871.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0902819"},{"key":"e_1_3_5_11_1","unstructured":"Olumiant Summary of Product Characteristics [Internet]. The Netherlands: European Medicines Agency. 2023. [cited 2022 Mar 20]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/olumiant-epar-product-information_en.pdf"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2012.755254"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10638.x"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac068"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-020-00218-3"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18115679"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-022-00500-6"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002674"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-022-00463-8"},{"key":"e_1_3_5_20_1","unstructured":"BSRBR-RA study [Internet]. Manchester: University of Manchester. 2022. [cited 2022 Sep 5]. Available from: https:\/\/www.bsrbr.org"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead074"},{"key":"e_1_3_5_22_1","unstructured":"The Swiss Registry for Inflammatory Rheumatic Diseases [Internet]. Zurich: SCQM Foundation. 2022. [cited 2022 Sep 5]. Available from: https:\/\/www.scqm.ch\/en\/"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-eular.3770"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05021-7"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-019-00177-4"},{"issue":"3","key":"e_1_3_5_26_1","first-page":"485","article-title":"Real-world experience with tofacitinib for the treatment of rheumatoid arthritis","volume":"37","author":"Caporali R","year":"2019","unstructured":"Caporali R, Zavaglia D. Real-world experience with tofacitinib for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2019;37(3):485\u2013495.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01501-z"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.1745"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8101548"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.3906\/sag-2007-123"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.5582\/ddt.2022.01028"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.191252"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez324"},{"key":"e_1_3_5_34_1","unstructured":"US Food and Drug Administration. FDA requires warnings about increased risk of serious heart-related events cancer blood clots and death for JAK inhibitors that treat certain chronic inflammatory conditions. Approved uses also being limited to certain patients. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001994"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24007"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.210346"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507247"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210094"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206478"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1608345"},{"key":"e_1_3_5_42_1","unstructured":"A Study of Baricitinib (LY3009104) in Participants with Rheumatoid Arthritis (RA-BRIDGE). ClinicalTrials.gov ID NCT03915964. [cited 2024 Aug 28]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT03915964"},{"key":"e_1_3_5_43_1","unstructured":"A Study of Baricitinib in Participants with Rheumatoid Arthritis (RA-BRANCH). ClinicalTrials.gov ID NCT04086745. [cited 2024 Aug 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04086745"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/03007995.2024.2416979","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T12:49:42Z","timestamp":1746794982000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/03007995.2024.2416979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,22]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1080\/03007995.2024.2416979"],"URL":"https:\/\/doi.org\/10.1080\/03007995.2024.2416979","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-12-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}